Related Experiment Video

Updated: Jul 10, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K

Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child

R Abelman1, L M Spring1, R Corcoran1

  • 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 23, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

Related Experiment Videos

Last Updated: Jul 10, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Hybridoma Technology01:31

Hybridoma Technology

14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K

Articles linked to this work by shared authors, journal, and citation graph.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

ESMO open·2026

Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.

NPJ breast cancer·2026

Navigating Parenthood during Medical Training.

Irish medical journal·2026

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

ESMO open·2026

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Recent advances in cell therapy for AML/MDS.

International journal of hematology·2026

Therapeutic effects of trans-3-methoxy-β-nitrostyrene in rat model of monocrotaline-induced pulmonary hypertension.

European journal of pharmacology·2026

A dual functional hybrid lipid-polymeric nanoparticle co-loaded coenzyme Q10 and siRNA TNFα for anti-inflammatory skin therapy.

International journal of pharmaceutics·2026

Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.

Cell reports. Medicine·2026

Preclinical evaluation of entecavir as a fetal hemoglobin inducer using in vitro, in vivo, network pharmacology, and molecular docking approaches.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Extracorporeal photopheresis: A comprehensive review from a transfusion medicine perspective.

Hematology, transfusion and cell therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us